(Q36871712)

English

Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

scientific article published on July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

phase II clinical trial

0 references

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

David M Kurtz

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Loren K Tschetter

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Jacob B Allred

3

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Susan M Geyer

4

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Paul J Kurtin

5

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Wesley D Putnam

6

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Kendrith M Rowland

7

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Martin Wiesenfeld

8

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Gamini S Soori

9

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Richard C Tenglin

10

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Albert M Bernath

11

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Thomas E Witzig

12

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1290-1298

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

The IL-4 receptor: signaling mechanisms and biologic functions

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

IL-4/IL-13 signaling beyond JAK/STAT

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Molecular pathogenesis of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701355028

21 January 2018

Identifiers

10.1080/10428190701355028

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36871712&oldid=2087963388"